Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade

Author(s): Steven G. Chrysant, George S. Chrysant, Catherine Chrysant and Mohammad Shiraz

Volume 5 , Issue 2 , 2010

Page: [89 - 95] Pages: 7

DOI: 10.2174/157488410791110742

Price: $65

Abstract

The cardiovascular disease continuum is a sequence of events, which begins with a host of risk factors consisting of diabetes mellitus, dyslipidemia, hypertension, smoking and visceral obesity. If left untreated, it will inexorably progress to atherosclerosis, CAD, myocardial infarction, left ventricular remodeling, LVH, left ventricular enlargement, and eventually end-stage heart failure and death. Treatment intervention at any stage of its course will prevent or delay its further progression. However, the best results are expected to be achieved when treatment is initiated at the beginning, or at an early stage of its course. A Pub-Med/MEDLINE search was conducted for relevant English language, randomized clinical trials and epidemiologic studies for the years 1995-2009 using the terms, cardiovascular continuum, obesity, hyperlipidemia, diabetes mellitus, hypertension, metabolic syndrome, renal disease, stroke, and blockers of the renin angiotensin system (RAS). A total of 34 pertinent studies were selected for review. This concise review will focus on prevention and the aggressive treatment of the existing cardiovascular risk factors with emphasis on the blockers of RAS, and demonstrate that RAS blockers are the best drugs for its treatment.

Keywords: Cardiovascular disease continuum, cholesterol, diabetes, hypertension, obesity, ACE inhibitors, ARBs


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy